Table 5 Summary of results of the Monte Carlo simulation for the Rett syndrome case using a discount rate of \(r=11\%\)
From: Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences
| Â | Â | Monte Carlo simulation | ||
|---|---|---|---|---|
| Â | Â Expected rNPV after each phase | Average rNPV | Standard deviation of rNPV | Upper bound on the rNPV |
Discovery, preclinical development, and phase 1 | 46.9 | 37.40 | 25.32 | 138.80 |
Phase 2 | 148.0 | 135.62 | 55.47 | 374.56 |
Phase 3 | 339.2 | 334.72 | 91.10 | 716.11 |
FDA submission-to-launch | 455.7 | 450.36 | 107.57 | 900.73 |
Overall | 23.3 | 17.52 | 15.34 | 80.06 |